GENPET is an observational study looking at the use of PET scanning in men with a germline BRCA1/2 mutation who have developed prostate cancer.

Men with germline BRCA1/2 mutations are more susceptible to prostate cancer than men without a mutation.

The aim of the study is to determine if FCH-PET-CT imaging is superior to combined bone scan and MRI of the abdomen & pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostate cancer and who have a germline BRCA 1/2 mutation.

The study is currently open to recruitment at the Royal Marsden Hospital.

Eligibility:

• Patients with a new diagnosis of prostate cancer who carry a germline BRCA mutation, regardless of Gleason score or PSA
• Patients who carry a germline BRCA mutation and who previously underwent radical treatment (surgical or radiotherapy) and are now presenting with biochemical relapse as defined by the EAU guidelines
• Men with prostate cancer and a germline BRCA mutation on active surveillance for at least 6 months, with a PSA doubling time of 6 months or less